Ghost Tree Capital LLC Trims Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Ghost Tree Capital LLC reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) by 23.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 250,000 shares of the company’s stock after selling 75,000 shares during the quarter. Apellis Pharmaceuticals comprises about 2.8% of Ghost Tree Capital LLC’s investment portfolio, making the stock its 4th biggest position. Ghost Tree Capital LLC owned 0.23% of Apellis Pharmaceuticals worth $12,703,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in APLS. Virginia Retirement Systems ET AL boosted its position in shares of Apellis Pharmaceuticals by 7.1% during the first quarter. Virginia Retirement Systems ET AL now owns 6,000 shares of the company’s stock valued at $305,000 after buying an additional 400 shares during the period. Great West Life Assurance Co. Can boosted its position in shares of Apellis Pharmaceuticals by 15.5% during the first quarter. Great West Life Assurance Co. Can now owns 3,734 shares of the company’s stock valued at $202,000 after buying an additional 500 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Apellis Pharmaceuticals by 9.1% during the first quarter. Ameritas Investment Partners Inc. now owns 6,090 shares of the company’s stock valued at $309,000 after buying an additional 510 shares during the period. American International Group Inc. boosted its position in shares of Apellis Pharmaceuticals by 2.2% during the first quarter. American International Group Inc. now owns 38,816 shares of the company’s stock valued at $1,972,000 after buying an additional 828 shares during the period. Finally, US Bancorp DE boosted its position in shares of Apellis Pharmaceuticals by 391.2% during the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after buying an additional 884 shares during the period. 82.75% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Stock Down 1.4 %

Apellis Pharmaceuticals stock opened at $67.57 on Friday. The business has a fifty day moving average of $57.92 and a two-hundred day moving average of $50.08. The firm has a market cap of $7.42 billion, a P/E ratio of -9.98 and a beta of 1.51. The company has a quick ratio of 7.19, a current ratio of 7.57 and a debt-to-equity ratio of 0.57. Apellis Pharmaceuticals, Inc. has a twelve month low of $27.50 and a twelve month high of $70.00.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last issued its quarterly earnings results on Monday, August 8th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.03). Apellis Pharmaceuticals had a negative return on equity of 272.25% and a negative net margin of 660.59%. During the same period last year, the company earned ($2.72) EPS. On average, analysts forecast that Apellis Pharmaceuticals, Inc. will post -5.92 earnings per share for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other news, Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $39.29, for a total transaction of $49,112.50. Following the transaction, the director now directly owns 263,774 shares of the company’s stock, valued at $10,363,680.46. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Victoria L. Brown sold 2,698 shares of the company’s stock in a transaction on Friday, June 17th. The stock was sold at an average price of $45.00, for a total value of $121,410.00. Following the transaction, the insider now directly owns 24,974 shares of the company’s stock, valued at approximately $1,123,830. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $39.29, for a total value of $49,112.50. Following the completion of the transaction, the director now directly owns 263,774 shares in the company, valued at $10,363,680.46. The disclosure for this sale can be found here. Over the last three months, insiders have sold 142,289 shares of company stock valued at $8,071,218. Corporate insiders own 8.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on APLS. Stifel Nicolaus boosted their price target on Apellis Pharmaceuticals from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday. Citigroup boosted their price target on Apellis Pharmaceuticals from $81.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, July 20th. The Goldman Sachs Group boosted their price target on Apellis Pharmaceuticals from $91.00 to $102.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Raymond James boosted their price target on Apellis Pharmaceuticals from $102.00 to $113.00 and gave the company a “strong-buy” rating in a report on Tuesday, August 9th. Finally, HC Wainwright started coverage on Apellis Pharmaceuticals in a report on Tuesday, July 19th. They issued a “buy” rating and a $75.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $72.93.

Apellis Pharmaceuticals Company Profile

(Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Read More

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.